Interestingly, in case of tumor recurrence, patients that received adjuvant GEMOX showed a trend towards worse median post-relapse OS when compared to those without adjuvant therapy (8.0 vs. 15.2 months; HR 1.55 (95% CI 0.98–2.47); p = 0.06).
The first phase III study in this field confirmed the highly significant effectiveness of ivosidenib in patients with isocitrate dehydrogenase 1 (IDH1) mutations, and promising results for pemigatinib in patients with fibroblast growth factor receptor 2 (FGFR2) fusions were obtained [ 8 , 9 ].